| Business Summary | | NuOncology
Labs,
Inc.
is
a
development
stage
company
engaged
in
the
cancer
research
&
clinical
testing
laboratories
industries.
In
its
pharmaceutical
research
NuOncology
Labs
engages
in
research,
development,
testing
and
licensing
of
promising
pharmaceuticals
and
other
cancer
treatments.
In
its
clinical
laboratory
business,
the
Company
conducts
predictive
drug
response
tests
for
the
optimization
of
chemotherapeutic
cancer
treatment
of
individual
cancer
patients
and
provides
other
contracted
clinical
testing
services.
Currently,
the
Company's
subsidiaries,
Paracure
and
IPRLL,
have
four
issued
patents
and
three
additional
allowed
patent
applications.
Additionally,
the
subsidiaries
have
four
U.S.
and
12
international
pending
patent
applications
directed
to
various
chemotherapy
compounds
and
methods
of
cancer
treatment. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | NLAB
is
a
development
stage
company
engaged
in
the
cancer
research
and
clinical
testing
laboratories
industries.
It
currently
supports
the
research,
development,
testing,
and
licensing
of
cancer
treatments
and
the
delivery
of
predictive
chemosensitivity
tests
for
the
optimization
of
contemporary
cancer
treatment.
For
the
fiscal
year
ended
12/31/98,
revenues
totalled
$34
thousand.
Net
loss
totalled
$597
thousand.
Results
are
not
comparable
due
to
the
company's
4/98
inception. | More
from
Market Guide: Significant
Developments |
| | | | FY1998 Pay | |
| Philip Enlow, 72 Chairman,
CEO | $100K | Fraser Baker, Ph.D., 58 Sr.
VP Clinical Testing & Research, Director | 100K | Robert Thomas, 54 Sr.
VP Bus. Devel., Director | 100K | Dollar amounts are as of 31-Dec-1998 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|